- Under the radar the FDA has introduced a new regulatory pathway for insulin biosimilars (generic copies of biologic drugs).
- “Today is a milestone for the future of insulin and other important treatments – potentially a new era of proposed biosimilar and interchangeable insulin products.”
- This will increase competition.
- Likely a big issue for the insulin oligopoly Sanofi, Novo Nordisk and Eli Lilly.
